Core Insights - The article highlights the progress and vision of the Shenzhen Institute of Advanced Technology (SMART) under the leadership of Yan Ning, emphasizing her commitment to scientific research and the development of a robust biomedical platform in Shenzhen [2][3][10]. Group 1: Progress of SMART - Yan Ning expresses satisfaction with the progress of SMART, stating it has exceeded expectations since its establishment [3]. - The institute has successfully recruited several prominent Principal Investigators (PIs), enhancing its research capabilities [5]. - The Shenzhen Bay Laboratory, which operates in conjunction with SMART, has also seen significant growth, with over 60 young PIs joining [5][10]. Group 2: Research Focus - Yan Ning's research primarily revolves around transport proteins and ion channels related to human diseases, with a focus on understanding their three-dimensional structures [8][9]. - The concept of "life dark matter" is introduced, referring to the unknown substances in life sciences, such as carbohydrates and lipids, which are crucial for understanding life's essence and potential applications [9][10]. - The research aims to bridge the gap between basic science and practical applications, striving for impactful contributions to human health [10]. Group 3: Vision for the Future - Yan Ning envisions that, through collective efforts, Shenzhen will hold a significant position in the global biomedical landscape in the next 10 to 20 years [6]. - The institute aims to create an environment where researchers can focus on their work without administrative burdens, promoting a culture of "research without worries" [10][11]. - The ongoing construction of SMART's facilities is progressing rapidly, with plans for completion and operational readiness in the near future [11].

Core Viewpoint - The article discusses the challenges faced by young children during summer, particularly focusing on the issues of constipation and dry stools, and provides solutions to alleviate these problems. Group 1: Causes of Constipation in Children - High temperatures lead to excessive sweating in children, which can result in dehydration and trigger the body's "water conservation mechanism," causing the intestines to absorb too much water, leading to hard stools [3] - Children's appetite tends to decrease in summer, making them less interested in fiber-rich foods like fruits and vegetables, which are essential for maintaining healthy bowel movements [3] - Reduced outdoor activities due to high temperatures result in lower physical activity levels, further slowing down intestinal motility and exacerbating constipation [3] Group 2: Solutions to Alleviate Constipation - Dietary adjustments should include providing children with fiber-rich foods such as finely chopped broccoli, spinach, ripe bananas, pears, and dragon fruit, along with whole grains like oats and corn [3][4] - Parents should ensure children drink adequate amounts of water, approximately 1000 - 1300ml daily for those aged 2-3 years, following the principle of "small amounts frequently" [3] - Regular physical activity is crucial; parents can engage children in outdoor activities during cooler times of the day or indoor exercises that promote movement, aiming for 20 - 30 minutes of activity [4] Group 3: Additional Measures - Supplementing with probiotics like Mommy Love (Bacillus subtilis and Bacillus licheniformis) can help regulate gut flora and enhance digestive function, aiding in the resolution of constipation [6] - In cases of severe constipation, the use of lactulose-based medications may be considered to assist in bowel movements [6] - Emphasizing the importance of parental care and attention to detail in daily routines can significantly help children avoid constipation and enjoy a comfortable summer [6]

乌克兰与美国围绕矿产协议的拉锯战堪称"马拉松式谈判"。泽连斯基2月底白宫之行因开采权补偿问题不欢而散，特朗普政府试图将乌克 兰矿产作为军援"抵押品"的意图暴露无遗。根据乌克兰经济部披露的备忘录修订记录，协议文本中"美国优先开发权"条款被删除，转为设 立乌克兰重建投资基金。这个变化背后是斯维里坚科团队在4月11日技术磋商中，将原本美方主导的矿产开发模式调整为国际联合投资框 架。 泽连斯基资料图 协议刚落地，欧盟的关税重锤就砸向基辅。布鲁塞尔拟将乌克兰玉米进口额度从每年470万公吨压缩至65万公吨，禽肉配额砍掉30%，糖 类进口量直接腰斩。乌克兰农业部测算显示，仅玉米出口缩水就可能造成18亿欧元损失，这个数字相当于乌克兰2024年农业出口预算的 12%。更棘手的是欧盟提出的"月度配额拆分制"，这种动态管控机制让乌克兰企业完全丧失市场预期。 波兰农民开着拖拉机封锁边境口岸的画面还没从公众记忆里消退，法国农业工会又放出"全面禁运乌克兰鸡蛋"的威胁。欧盟农业委员汉森 承认，内部至少有六个成员国要求设立"农业保护红线"。波兰作为乌克兰最大陆路贸易通道，其4月15日启动的粮食禁运已导致乌西地区 20万吨谷物滞留，敖德萨港的 ...

Group 1: Financial Performance - The company's revenue for 2024 reached 98,355.45 million, a year-on-year increase of 10.42% [2] - Net profit attributable to shareholders was 1,365.17 million, up 119.02% year-on-year, with the parent company's net profit at 5,635.84 million, increasing by 838.39% [2] - In Q1 2025, revenue was 28,268.07 million, showing a growth of 36.23% year-on-year, while net profit rose to 1,453.85 million, up 26.13% [2] Group 2: Profitability and Margins - The gross margin for 2024 was 47.67%, an increase of 0.66 percentage points compared to 2023 [3] - The company plans to enhance gross margins through continuous improvement in production processes and cost reduction [3] Group 3: Product Performance - Sales revenue from contrast agents reached 58,804.95 million in 2024, a growth of 9.87% year-on-year [3] - Sales of antidiabetic products grew by 33.24% year-on-year, attributed to successful bidding and subsequent contracts [4] Group 4: Research and Development - R&D expenses for 2024 were 6,923.81 million, a decrease of 43.40% compared to the previous year, due to a more stable phase in R&D and improved efficiency [5] - The company has 12 projects under review and 23 new R&D projects initiated [5] Group 5: Subsidiary Developments - The acquisition of Tianyuan Pharmaceutical increased the number of traditional Chinese medicine products to 59, with a focus on promoting unique products [8] - The construction of the production base for Luzhibao Pharmaceutical is ongoing, with trial production expected to start within the year [7] Group 6: Investor Relations and Governance - The total number of shareholders decreased by 7.37% by the end of Q1 2025, indicating a shift towards attracting more quality investors [10] - The company emphasizes a stable and scientific dividend policy to ensure sustainable returns to shareholders [10] Group 7: Debt Management - The company has sufficient funds to repay the principal and interest of convertible bonds due next year, ensuring no repayment risk [11]

证券代码：300016 证券简称：北陆药业 债券代码：123082 债券简称：北陆转债 2025 年 4 月 21 日投资者关系活动记录表 编号：【2025】第 013 号 投资者关系 活动类别 √特定对象调研 □分析师会议 □媒体采访 □业绩说明会 □新闻发布会 □路演活动 □现场参观 □其他 参与单位名称 及人员姓名 浙商证券：王明路 太平洋资管：汪奇立 华商基金：余丹妮 银华基金：李宛达 华夏基金：袁绮蔓 时 间 2025 年 4 月 21 日 地 点 公司会议室 上市公司接 待人员姓名 证券事务代表：孙志芳 投资者关系活动 主要内容介绍 Q1、公司 2024 年度经营情况 2024 年度，公司继续以成为"中国医药制造百强企业"为中长期 发展目标，践行"化药+中药"双轮驱动的业务模式：化药板块主要 聚焦于对比剂产品、降糖类产品、原料药等化学药品的生产、研发、 营销等工作。中成药板块，公司自主研发的九味镇心颗粒持续拓展市 场；2024 年 6 月，公司通过收购天原药业 80%股权，将中成药产品数 量增加至 59 个，打造了较为丰富的中成药产品矩阵，实现了在中枢神 经、清热解毒、补益类等领域的布局；以九味镇 ...

以下文章来源于TopDigital ，作者TD TopDigital . TopDigital 关注数字时代如何做好品牌营销。专访大品牌和500强，深挖营销案例背后的品牌生意方法 论。通过内容、活动及赛事，为100万+品牌营销人士提供专业服务。 不知道大家有没有发现，这几年去逛超市、便利店，突然发现货架上多了一种叫作「梅冻」的产品。吃 起来带着一股梅子的酸甜，热量也不高，当我发现自己复购了一遍又一遍的时候，对这个产品产生了好 奇，查了查资料。 原来这个不知道最近哪一年冒出来的黑马产品，背后有这么多故事。 先说大背景，「梅冻」定位为"天然果冻"，它所属的休闲零食市场，市场规模高达1.16万亿，不过竞 争格局分散，同质化严重是最大的挑战之一。 关于同质化这一点，来伊份首席增长官姜振多、三全食品总裁陈希、喜茶等知名企业（及高层）均公开 表达过担忧——"趋同的产品将消耗用户热情"、"同质化竞争已导致价格战泛滥"…… 再说说小背景，「梅冻」所属公司溜溜梅的主要产品为果脯蜜饯。 图片来源：微博@溜溜梅 果脯蜜饯属于休闲零食市场里的一大子类别，当今消费者越来越偏好健康、低糖低盐、纯净配料的零 食，除了上述同质化问题之外，这 ...

Overview - The women's health supplement market in China is projected to reach a market size of 268.28 billion yuan in 2024, driven by increased health awareness and disposable income among women [1][10] - The market is segmented into various categories, with nutritional supplements accounting for approximately 30.5%, beauty and skincare products for 22.2%, and weight loss supplements for 21.2% [1][10] Market Policies - Recent policies such as the "Quality Strong Country Construction Outline" and "Measures to Restore and Expand Consumption" have been implemented to improve market order and support the women's health supplement industry [3][4] Industry Chain - The upstream of the women's health supplement industry includes suppliers of raw materials like herbal medicine, biological agents, and plant extracts, which significantly impact production costs [6] - The downstream consists of various sales channels including pharmacies, supermarkets, specialty stores, and e-commerce platforms [6] Consumer Demographics - In 2024, the female population in China is estimated to be 689.19 million, representing 48.94% of the total population, providing a solid consumer base for the women's health supplement industry [8] Competitive Landscape - The industry features numerous participants, including domestic companies like汤臣倍健 (Tongrentang) and东阿阿胶 (Dong'e Ejiao), as well as international brands like Swisse and Amway [12][14] - Tongrentang has established itself as a leader with a diverse product line and strong nutritional research capabilities, while Dong'e Ejiao focuses on traditional products catering to specific demographic needs [12][14][16] Industry Trends - Future demand for women's health supplements is expected to shift from single-function products to multi-dimensional solutions, focusing on immune support, weight management, and beauty [18] - There is a growing preference for natural ingredients and products that combine traditional Chinese health elements with modern formulations [18]

Core Insights - The report titled "2025-2031 China Women's Health Products Industry Market Panorama Survey and Investment Potential Research Report" has been a bestseller for two consecutive years since its publication in 2024, serving as a valuable reference for companies to understand and explore the market and formulate strategic directions [1] - The report analyzes the future market trends of the women's health products industry from a macroeconomic and industrial development perspective, identifying the industry's growth potential and forecasting its future prospects [1] Industry Overview - The women's health products industry in China is segmented into eight categories: nutritional supplements (30.5%), beauty and skincare products (22.2%), weight loss products (21.2%), fatigue relief products (7.6%), sleep improvement products (7.5%), immune enhancement products (5.0%), blood sugar reduction products (3.8%), and blood lipid reduction products (2.2%) [3] - The market size of the women's health products industry in China is projected to reach 268.28 billion yuan in 2024, driven by increasing health awareness among women and rising disposable incomes [3] Supply Chain Dynamics - The upstream of the women's health products industry includes suppliers of raw materials such as traditional Chinese medicine, biological agents, plant extracts, and protein powders, with raw material costs being a significant factor affecting production costs and profit margins [6] - The downstream includes various sales channels such as pharmacies, supermarkets, specialty health stores, and e-commerce platforms, with female consumers being the primary target audience [6] Competitive Landscape - The industry features numerous participants, including domestic companies like Tongrentang, Dong'e Ejiao, and international brands like Centrum and Amway, with each company catering to different consumer needs and preferences [9] - Tongrentang leverages its rich product line and nutritional research capabilities to meet the diverse needs of women across different age groups and physiological stages [9] Future Outlook - The report provides a comprehensive analysis of the women's health products industry's development trends, competitive landscape, and strategic recommendations for companies looking to invest in this growing market [1][15] - The data in the report is sourced from authoritative institutions, industry associations, and in-depth research, ensuring accuracy and reliability for stakeholders [15][16]